{
  "id": 19109231,
  "title": "SK Biopharma Expands U.S. Innovation Hub",
  "url": "https://urgent.news/2026/11/09/sk-biopharma-expands-u-s-innovation-hub",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-09T07:06:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=280813"
  },
  "original_language": "en",
  "account": "SK Biopharma has finalized the choice of 11 companies for its U.S. innovation hub, SK Life Science LinX. The open innovation platform, launched in June, brings together a diverse group of firms from pharmaceuticals to AI and medical devices. These companies will leverage SK Biopharma's local resources, such as 160 pyeong of office space and meeting rooms, to seek business opportunities in the U.S. market and expand their networks.\n\nSK Biopharma will act as a K-bio bridge, connecting Asia's strong R&D capabilities with the advanced North American market. By sharing its expertise in clinical development, FDA approval, and business development, SK Biopharma aims to help Korean companies establish themselves locally. The Korea Trade-Investment Promotion Agency will support local partner discovery through company assessments and management of an expert pool.\n\nSK Biopharma will offer individualized support through a one-on-one expert advisory program in five core areas: FDA and licensing, corporation establishment and tax, IP and patent strategy, clinical development and technology transfer, and business development. The company plans to use local institutions and expert pools to provide tailored strategies for each company's specific needs.\n\nSpeaking from experience, SK Biopharma, the first Korean company to bring an epilepsy treatment, cenobamate, to the U.S. market, will share its practical know-how through seminars and training programs. The U.S. market requires not only technological capability but also local business experience and strong networks, according to SK Biopharma president Lee Dong-hoon. Through the LinX platform, SK Biopharma plans to foster cooperation in areas like AI-based drug candidate discovery, technology advisory services, and licensing agreements.",
  "summary": "SK Biopharmaceuticals said it has completed the selection of resident companies for \"SK Life Science LinX,\" an open innovation platform launched in June inside the office of its U.S. subsidiary SK Life Science, and will begin operating customized support programs.The newly selected companies span a",
  "key_points": [
    "SK Biopharma selects 11 companies for U.S. innovation hub SK Life Science LinX.",
    "Open innovation platform leverages SK Biopharma's local resources in U.S. market.",
    "SK Biopharma offers tailored support through expert advisory program in five key areas."
  ],
  "editors_take": "By providing specialized regulatory and clinical expertise, SK Biopharma is positioning itself as a vital gateway for Asian biotech firms seeking to navigate the complexities of the North American market.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}